SCHEMBL6311706

SCHEMBL6311706

CN(C)C1CC(=O)c2cccc3[nH]cc(c23)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.48
HTR1A P08908 5/20 0.42
HTR2A P28223 2/20 0.42
HTR2C P28335 2/20 0.42
HTR7 P34969 2/20 0.42
HTR2B P41595 2/20 0.42
HTR6 P50406 2/20 0.42
DRD2 P14416 2/20 0.41
DRD3 P35462 2/20 0.41
KDM4E B2RXH2 5/20 0.41
MEN1 O00255 4/20 0.41
MAPT P10636 4/20 0.41
KMT2A Q03164 4/20 0.41
USP2 O75604 2/20 0.41
RECQL P46063 1/20 0.41
PLEC Q15149 1/20 0.41
ALDH1A1 P00352 4/20 0.40
HSD17B10 Q99714 4/20 0.40
CYP3A4 P08684 3/20 0.40
CYP2D6 P10635 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30797718 0.84 SLC6A4 (0.46) HTR1ADRD2DRD3KDM4EMEN1
SCHEMBL9790419 0.84 SLC6A4 (0.46) HTR1ADRD2DRD3KDM4EMEN1
SCHEMBL6307694 0.78 HTR2A (0.43) PARP1HTR1AHTR2AHTR2CHTR7
SCHEMBL261487 0.72 PARP1 (0.64) PARP1HTR1AHTR7HTR2BHTR6
SCHEMBL26266600 0.72 MEN1 (0.52) DRD2DRD3KDM4EMEN1MAPT
SCHEMBL21510708 0.70 PARP1 (0.49) PARP1HTR1AHTR2AHTR2CHTR7
SCHEMBL10955932 0.70 PARP1 (0.60) PARP1DRD2DRD3KDM4EMAPT
SCHEMBL23249538 0.70 HTR1A (0.46) HTR1AHTR2AHTR2CHTR7HTR2B
SCHEMBL23248780 0.70 HTR1A (0.46) HTR1AHTR2AHTR2CHTR7HTR2B
SCHEMBL23248781 0.70 HTR1A (0.46) HTR1AHTR2AHTR2CHTR7HTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043387-A1 Tricyclic indole compounds having an affinity against serotonin receptors FUKUI YOSHIKAZU (JP) 2005-02-24 US disclosed
US-6858640-B2 Tricyclic indole compounds having affinity for serotonin receptor SHIONOGI & CO., LTD. (JP) 2005-02-22 US disclosed
US-20030236295-A1 Tricylic indole compounds having affinity for serotonin receptor SHIONOGI & CO., LTD. (JP) 2003-12-25 US disclosed
EP-1325909-A1 TRICYCLIC INDOLE COMPOUNDS HAVING AFFINITY FOR SEROTONIN RECEPTOR SHIONOGI & CO., LTD. (JP) 2003-07-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043387-A1 Tricyclic indole compounds having an affinity against serotonin receptors HTR4, TPH1, HRH4 PARP1 2300/4885HTR1A 6/4885HTR2A 15/4885
US-20030236295-A1 Tricylic indole compounds having affinity for serotonin receptor HTR4, HRH4, TPH1 PARP1 2739/4885HTR1A 7/4885HTR2A 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.